Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine June 2020, 61 (6) 14A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: JNM editor-in-chief Johannes Czernin talks with Howard Soule, of the Prostate Cancer Foundation, about supporting and encouraging research in an environment of rapidly changing scientific knowledge and clinical practice.

Page 774

Leading in a time of pandemic: Johnese Spisso, president of UCLA Health and CEO of the UCLA Hospital System, discusses with JNM editor-in-chief Johannes Czernin challenges and strategies in managing health-care delivery during the COVID-19 outbreak.

Page 777

Bombesin imaging in cancer: Baratto and colleagues offer a state-of-the-art overview of the bombesin receptor family, with a focus on gastrin-releasing peptide receptors and on applications in prostate and breast cancers.

Page 792

Molecular imaging of bone metastases: Cook and Goh provide an educational review of the role of new molecular and hybrid methods, including SPECT/CT, PET/CT, and whole-body MR, for imaging bone metastases.

Page 799

Aromatase imaging in breast cancer: Biegon and colleagues validate and optimize PET imaging with 11C-vorozole for in vivo measurement of aromatase expression in individual breast cancer lesions in postmenopausal women.

Page 807

PET/CT radiomics in lung cancer SBRT: Dissaux and colleagues develop and evaluate a prognostic 18F-FDG PET/CT radiomic signature in early-stage non–small cell lung cancer patients treated with stereotactic body radiotherapy.

Page 814

18F-FDG PET/CT and hyperprogressive cancer: Castello and colleagues use 18F-FDG PET/CT to investigate the prevalence of hyperprogressive disease as a pattern of response during treatment of non–small cell lung cancer with immune checkpoint inhibitors.

Page 821

11C-Choline PET/CT in recurrent prostate cancer: Michaud and colleagues report on the performance of 11C-choline PET/CT in detecting biochemically recurrent prostate cancer in a large non-European cohort and describe patterns of recurrence.

Page 827

Integrated roadmap for fluorescence guidance: Meershoek and colleagues detail the role of positional data from SPECT/CT in providing a 3D preoperative imaging road map for fluorescence-guided surgery in prostate cancer.

Page 834

Co-clinical imaging: Savaikar and colleagues develop and optimize image metrics for 18F-FDG PET to assess response to combination docetaxel and carboplatin therapy in a co-clinical trial involving triple-negative breast cancer patient–derived xenografts.

Page 842

PARP-1–targeted Auger therapy: Lee and colleagues assess the cytotoxicity of chromatin-targeted Auger therapy in preclinical models of high-risk neuroblastoma and discuss the potential for use in micrometastatic disease.

Page 850

177Lu-PSMA-617 in prostate cancer: Violet and colleagues report longer-term outcomes in an expanded cohort from a trial of this prostate-specific membrane–targeting radioligand in men with metastatic castration-resistant prostate cancer.

Page 857

3-Year freedom from progression in BCR: Emmett and colleagues describe the predictive value of 68Ga-prostate-specific membrane antigen PET for 3-y freedom from progression in men with biochemical recurrence of prostate cancer undergoing salvage radiotherapy.

Page 866

68Ga-PSMA PET/CT and PTEN–loss PCa: Wang and colleagues explore the value of 68Ga-prostate-specific membrane antigen PET/CT for detection of phosphatase and tensin homolog–loss prostate cancer.

Page 873

18F-DCFPyL PET/CT in prostate cancer: Mena and colleagues investigate the lesion detection rate of this prostate-specific membrane antigen–targeted PET agent in patients with biochemically relapsed prostate cancer after primary local therapy.

Page 881

64Cu-DOTATATE in NETs: Delpassand and colleagues prospectively determine the lowest optimal dose of this tracer and evaluate its diagnostic performance and safety in a phase III study of patients with somatostatin receptor–expressing neuroendocrine tumors.

Page 890

68Ga-DOTA-JR11 in NETs: Zhu and colleagues compare PET/CT results with this somatostatin receptor subtype 2–specific antagonist with those from 68Ga-DOTATATE in patients with metastatic, well-differentiated neuroendocrine tumors.

Page 897

Glucose transport in neuroendocrine prostate cancer: Bakht and colleagues evaluate the association between neuroendocrine gene signature and 18F-FDG uptake–associated genes in prostate cancer, including glucose transporters and hexokinases.

Page 904

18F-PI-2620 tau PET in humans: Mueller and colleagues assess the ability of imaging with this PET tracer to detect tau pathology in patients with Alzheimer disease and report on associated safety and tolerability.

Page 911

18F-PI-2620 kinetics and quantification: Bullich and colleagues detail the biodistribution, dosimetry, quantitative methods, and test–retest variability of this next-generation tau PET tracer in the human brain.

Page 920

Brain nicotine uptake and E-cigarettes: Solingapuram Sai and colleagues use 11C-nicotine PET to describe brain nicotine uptake and kinetics after inhalation from electronic cigarettes and compare these with results from smoking combustible cigarettes.

Page 928

Accuracy of 2-FDG determinations: Barrio and colleagues look at potential limitations of assuming 2-FDG as a surrogate for glucose metabolic rate and potential reasons for variability in the lump constant.

Page 931

  • © 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Next
Back to top

In this issue

Journal of Nuclear Medicine: 61 (6)
Journal of Nuclear Medicine
Vol. 61, Issue 6
June 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Jun 2020, 61 (6) 14A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Jun 2020, 61 (6) 14A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Can Intraoperative Fluorescence Imaging Identify All Lesions While the Road Map Created by Preoperative Nuclear Imaging Is Masked?
  • Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
  • Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
  • Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
  • A Conversation Between Howard Soule and Johannes Czernin
  • Diagnostic Value of 68Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study
  • 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial
  • Initial Studies with 11C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer
  • Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for 18F-FDG Imaging of PSMA-Suppressed Tumors
  • Pretreatment 18F-FDG PET/CT Radiomics Predict Local Recurrence in Patients Treated with Stereotactic Body Radiotherapy for Early-Stage Non–Small Cell Lung Cancer: A Multicentric Study
  • 3-Year Freedom from Progression After 68Ga-PSMA PET/CT–Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
  • Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
  • Hyperprogressive Disease in Patients with Non–Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18F-FDG PET/CT
  • Molecular Imaging of Bone Metastases and Their Response to Therapy
  • 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy
  • Evaluation of Dosimetry, Quantitative Methods, and Test–Retest Variability of 18F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain
  • 11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series
  • Rapid Brain Nicotine Uptake from Electronic Cigarettes
  • A Conversation Between Johnese Spisso and Johannes Czernin
  • Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-clinical 18F-FDG PET Imaging of Triple-Negative Breast Cancer Patient–Derived Tumor Xenografts
  • Does 2-FDG PET Accurately Reflect Quantitative In Vivo Glucose Utilization?
  • PARP-1–Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire